Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
Gilead Sciences aims to sustain its growth trajectory in Japan over the medium to long term, with new CAR-T therapy Tecartus (brexucabtagene autoleucel) and label expansions for breast cancer drug Trodelvy (sacituzumab govitecan) expected to give a further lift. “There’s…
To read the full story
Related Article
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Gilead Opens Japan Facility to Support CAR-T Delivery
October 7, 2025
- Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
- Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
BUSINESS
- Shionogi’s Olorofim Tops AmBisome in Day 84 Response Rate in Global PIII
October 22, 2026
- RaQualia to Receive 200 Million Yen from Hisamitsu as Pain Patch Enters PII
October 22, 2026
- Healios Eyes 2028 Launch of Kobe Cell Manufacturing Facility
October 22, 2026
- PreMedica Hit by Unauthorized Access; No Data Leak Confirmed
October 22, 2026
- Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…